Drug/Small Molecule:
indomethacin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with indomethacin that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105163

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
Spartan RX CYP2C19 System CYP2C19*17, CYP2C19*2, CYP2C19*3 , rs12248560 , rs4986893 , rs4244285

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP No VIP available No VIP available CYP2C19 *2A N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *3A N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs3842787 -248C>T, -249C>T, -278C>T, 125133507C>T, 130C>T, 356C>T, 50C>T, 5279C>T, 54298039C>T, C>T, PTGS1: P17L, Pro17Leu
C > T
5' UTR
Pro17Leu
rs4244285 24154G>A, 24154G>C, 47346080G>A, 47346080G>C, 681G>A, 681G>C, 96541616G>A, 96541616G>C, CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, Pro227=
G > A
G > C
Synonymous
Pro227Pro
rs4986893 22948G>A, 47344874G>A, 636G>A, 96540410G>A, CYP2C19*3, CYP2C19:636G>A, CYP2C19:G636A, Trp212Ter
G > A
Stop Codon
Trp212null
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • IMN
  • Indometacine
  • Indometacyna
  • Indomethacine
  • Indomethacinum
  • Indomethancin
  • Indomethazine
  • Indomethine
  • Indometicina
  • indomethacin
Trade Names
  • Amuno
  • Apo-Indomethacin
  • Argun
  • Arthrexin
  • Artracin
  • Artrinovo
  • Artrivia
  • Bonidin
  • Bonidon
  • Bonidon Gel
  • Catlep
  • Chibro-Amuno
  • Chrono-Indicid
  • Chrono-Indocid
  • Confortid
  • Dolcidium
  • Dolcidium Pl
  • Dolovin
  • Durametacin
  • Elmetacin
  • Flexin Continus
  • Hicin
  • Idomethine
  • Imbrilon
  • Inacid
  • Indacin
  • Indaflex
  • Indameth
  • Indmethacine
  • Indo-Lemmon
  • Indo-Phlogont
  • Indo-Rectolmin
  • Indo-Spray
  • Indo-Tablinen
  • Indocid
  • Indocid Pda
  • Indocid Sr
  • Indocin
  • Indocin I.V
  • Indocin I.V.
  • Indocin Sr
  • Indolar Sr
  • Indomecol
  • Indomed
  • Indomee
  • Indomethegan
  • Indomo
  • Indomod
  • Indoptic
  • Indoptol
  • Indorektal
  • Indoxen
  • Inflazon
  • Infrocin
  • Inteban Sp
  • Lausit
  • Liometacen
  • Metacen
  • Metartril
  • Methazine
  • Metindol
  • Miametan
  • Mikametan
  • Mobilan
  • Novo-Methacin
  • Novomethacin
  • Nu-Indo
  • Reumacide
  • Rhemacin La
  • Rheumacin La
  • Sadoreum
  • Tannex
  • Vonum
Brand Mixture Names

PharmGKB Accession Id:
PA449982

Description

Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.

Source: Drug Bank

Indication

For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Indomethacin is a prostaglandin G/H synthase (also known as cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. Indomethacin antagonizes COX by binding to the upper portion of the active site, preventing its substrate, arachidonic acid, from entering the active site. Indomethacin, unlike other NSAIDs, also inhibits phospholipase A2, the enzyme responsible for releasing arachidonic acid from phospholipids. Indomethacin is more selective for COX-1 than COX-2, which accounts for its increased adverse gastric effects relative to other NSAIDs. COX-1 is required for maintaining the protective gastric mucosal layer. The analgesic, antipyretic and anti-inflammatory effects of indomethacin occur as a result of decreased prostaglandin synthesis. Its antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

Source: Drug Bank

Pharmacology

Indomethacin, a NSAIA, with analgesic and antipyretic properties exerts its pharmacological effects by inhibiting the synthesis of prostaglandins involved in pain, fever, and inflammation. Indomethacin inhibits the catalytic activity of the COX enzymes, the enzymes responsible for catalyzing the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway. Indomethacin is known to inhibit two well-characterized isoforms of COX, COX-1 and COX-2, with greater selectivity for COX-1. COX-1 is a constitutively expressed enzyme that is involved in gastric mucosal protection, platelet and kidney function. It catalyzes the conversion of arachidonic acid to prostaglandin (PG) G2 and PGG2 to PGH2. COX-1 is involved in the synthesis pathways of PGE2, PGD2, PDF2a, PGI2 (also known as prostacyclin) and thromboxane A2 (TXA2). COX-2 is constitutively expressed and highly inducible by inflammatory stimuli. It is found in the central nervous system, kidneys, uterus and other organs. It also catalyzes the conversion of arachidonic acid to PGG2 and PGG2 to PGH2. In the COX-2-mediated pathway, PGH2 is subsequently converted to PGE2 and PGI2 (also known as prostacyclin). PGE2 is involved in mediating inflammation, pain and fever. Decreasing levels of PGE2 leads to decreased inflammation.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take with food or antacids to reduce irritation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Source: Drug Bank

Protein Binding

97%

Source: Drug Bank

Absorption

Bioavailability is approximately 100% following oral administration and 80-90% following rectal administration.

Source: Drug Bank

Half-Life

4.5 hours

Source: Drug Bank

Toxicity

The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD 50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.

Source: Drug Bank

Route of Elimination

Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion.

Source: Drug Bank

Chemical Properties

Chemical Formula

C19H16ClNO4

Source: Drug Bank

Isomeric SMILES

Cc1c(c2cc(ccc2n1C(=O)c3ccc(cc3)Cl)OC)CC(=O)O

Source: OpenEye

Canonical SMILES

COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O

Source: Drug Bank

Average Molecular Weight

357.788

Source: Drug Bank

Monoisotopic Molecular Weight

357.076785712

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Uricosurics Pathway, Pharmacodynamics
    A stylized diagram of a renal proximal tubule cell to show the role of uricosuric drugs in preventing reabsorption of uric acid in human kidney.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
CYP2C19
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
PTGS1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
SLC22A12

Drug Targets

Gene Description
GLO1 (source: Drug Bank)
PLA2G2A (source: Drug Bank)
PPARG (source: Drug Bank)
PTGDR2 (source: Drug Bank)
PTGR2 (source: Drug Bank)
PTGS1 (source: Drug Bank)
PTGS2 (source: Drug Bank)

Drug Interactions

Drug Description
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
indomethacin The NSAID, indomethacin, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Monitor for nephrotoxicity (source: Drug Bank)
indomethacin Monitor for nephrotoxicity (source: Drug Bank)
indomethacin Increases the effect and toxicity of indomethacin (source: Drug Bank)
indomethacin Increases the effect and toxicity of indomethacin (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
indomethacin The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid. (source: Drug Bank)
indomethacin The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
indomethacin The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide. (source: Drug Bank)
indomethacin Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. (source: Drug Bank)
acebutolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
acebutolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
acenocoumarol The NSAID increases the anticoagulant effect (source: Drug Bank)
acenocoumarol The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
alendronate Increased risk of gastric toxicity (source: Drug Bank)
alendronate Increased risk of gastric toxicity (source: Drug Bank)
anisindione The NSAID increases the anticoagulant effect (source: Drug Bank)
anisindione The NSAID, indomethacin, may increase the anticoagulant effect of anisindione. (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
atenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
betaxolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
betaxolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
bevantolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
bevantolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
bisoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
bisoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
bumetanide The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
bumetanide The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide. (source: Drug Bank)
carteolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
carteolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
carvedilol Risk of inhibition of renal prostaglandins (source: Drug Bank)
carvedilol Risk of inhibition of renal prostaglandins (source: Drug Bank)
cyclosporine Monitor for nephrotoxicity (source: Drug Bank)
cyclosporine Monitor for nephrotoxicity (source: Drug Bank)
dicumarol The NSAID increases the anticoagulant effect (source: Drug Bank)
dicumarol The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
diflunisal Diflunisal increases the effect and toxicity of indomethacin (source: Drug Bank)
diflunisal Diflunisal increases the effect and toxicity of indomethacin (source: Drug Bank)
esmolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
esmolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
ethacrynic acid The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
furosemide The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
furosemide The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide. (source: Drug Bank)
labetalol Risk of inhibition of renal prostaglandins (source: Drug Bank)
labetalol Risk of inhibition of renal prostaglandins (source: Drug Bank)
lithium The NSAID increases serum levels of lithium (source: Drug Bank)
lithium The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity. (source: Drug Bank)
losartan Indomethacin decreases the effect of losartan (source: Drug Bank)
losartan Indomethacin decreases the effect of losartan (source: Drug Bank)
methotrexate The NSAID increases the effect and toxicity of methotrexate (source: Drug Bank)
methotrexate The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. (source: Drug Bank)
metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
metoprolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
nadolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
nadolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
oxprenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
oxprenolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
penbutolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
penbutolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
pindolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
pindolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
probenecid Probenecid increases the effect/toxicity of indomethacin (source: Drug Bank)
probenecid Probenecid increases the effect/toxicity of indomethacin (source: Drug Bank)
propranolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
propranolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
sotalol Risk of inhibition of renal prostaglandins (source: Drug Bank)
sotalol Risk of inhibition of renal prostaglandins (source: Drug Bank)
timolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
timolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
torasemide The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic (source: Drug Bank)
torasemide The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide. (source: Drug Bank)
triamterene Risk of acute renal impairment with this combination (source: Drug Bank)
triamterene Risk of acute renal impairment with this combination (source: Drug Bank)
warfarin The NSAID increases the anticoagulant effect (source: Drug Bank)
warfarin The NSAID, indomethacin, may increase the anticoagulant effect of warfarin. (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin The NSAID increases serum levels of lithium (source: Drug Bank)
indomethacin The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity. (source: Drug Bank)
indomethacin Indomethacin decreases the effect of losartan (source: Drug Bank)
indomethacin Indomethacin decreases the effect of losartan (source: Drug Bank)
indomethacin The NSAID increases the effect and toxicity of methotrexate (source: Drug Bank)
indomethacin The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Probenecid increases the effect/toxicity of indomethacin (source: Drug Bank)
indomethacin Probenecid increases the effect/toxicity of indomethacin (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
indomethacin Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins. The NSAID, Indomethacine, may also antagonize the antihypertensive effect of Timolol. (source: Drug Bank)
indomethacin Risk of inhibition of renal prostaglandins. The NSAID, Indomethacine, may also antagonize the antihypertensive effect of Timolol. (source: Drug Bank)
indomethacin Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy. (source: Drug Bank)
indomethacin Risk of acute renal impairment with this combination (source: Drug Bank)
indomethacin Risk of acute renal impairment with this combination (source: Drug Bank)
indomethacin The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)
indomethacin Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to indomethacin: 9

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Co-inhibition of cyclooxygenase-2 and dihydropyrimidine dehydrogenase by non-steroidal anti-inflammatory drugs in tumor cells and xenografts. Anticancer research. 2009. Réti Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert opinion on drug metabolism & toxicology. 2009. Agúndez José A G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenetics and genomics. 2007. Lee Craig R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Characterization of methotrexate transport and its drug interactions with human organic anion transporters. The Journal of pharmacology and experimental therapeutics. 2002. Takeda Michio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1999. Legrand O, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
42211-101-11
DrugBank:
DB00328
ChEBI:
5918
KEGG Compound:
C01926
KEGG Drug:
D00141
PubChem Compound:
3715
PubChem Substance:
148696
46508291
IUPHAR Ligand:
1909
Drugs Product Database (DPD):
2143372
BindingDB:
17638
ChemSpider:
3584
Therapeutic Targets Database:
DAP000617
FDA Drug Label at DailyMed:
06de3c9d-63bf-47c1-f78c-4fbdd482928a

Clinical Trials

These are trials that mention indomethacin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.